Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases

Cancer Letters

Volumn 169, Issue 1, 2001, Pages 87-95

  Sotiriou, Christos ^a   Lacroix, Marc ^a   Lespagnard, Laurence ^a   Larsimont, Denis ^a   Paesmans, Marianne ^a   Body, Jean Jacques ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bone metastases; Breast cancer; Interleukin 11; Interleukin 6; Osteolysis; Prognostic factor

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 6; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-11; INTERLEUKIN-6; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER;

EID: 0035839310     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00524-9     Document Type: Article

References (40)

1. Mechanisms of bone metastasis
2. Parathyroid hormone-related protein and bone metastases
3. Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases
4. Interleukin-6 family of cytokines and gp130
5. Interleukin-11: Review of molecular, cell biology, and clinical use
6. Interleukin-11: A new cytokine critical for osteoclast development
7. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis
8. Cell biology of the osteoclast
9. Production and regulation of interleukin-11 by breast cancer cells
10. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11
11. CMF or anthracycline-based adjuvant chemotherapy for node-positive (N +) breast cancer (BC) patients (PTS): 4 Year results of a Belgian randomised clinical trial with predictive markers analysis
12. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up
13. Interleukin-6 positive follicular hyperplasia in the lymph node of a patient with rheumatoid arthritis
14. Immunocytochemical localisation of interleukin-1 alpha and interleukin- 6 in thyroid tissues from patients with neoplastic or autoimmune thyroid disorders
15. Cloning of a cDNA encoding interleukin 11, a stromal cell- derived lymphopoietic and hematopoietic cytokine
16. Detection of specific mRNAs in routinely processed dermatopathology specimens
17. Expression of and response to interleukin 6 (IL6) in human mammary tumors
18. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines
19. Clinical course and prognostic factors following bone recurrence from breast cancer
20. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles
21. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients
22. Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading
23. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis
24. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma
25. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer
26. The role of gp130-mediated signals in osteoclast development: Regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures
27. Interleukin-11 inhibits bone formation in vitro
28. The cellular actions of interleukin-11 on bone resorption in vitro
29. Protein production by osteoblasts: Modulation by breast cancer cell-derived factors
30. Increased interleukin-11 expression by breast cancer cells results in increased bone metastases in mice
31. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer
32. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin
33. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
34. Stimulation of interleukin-11 production from osteoblast-like cells by transforming growth factor-beta and tumor cell factors
35. Changes in sIL-6R and sTNF-Rs release by PMNs and the serum levels in breast cancer patients at different stages of treatment
36. Current use of bisphosphonates in oncology
37. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
38. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development